- 首页
- TNF Receptor
- Vercirnon sodium
Vercirnon sodium
An antagonist of CCR9
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥3775.003020.00- +
-
10mg￥5400.004320.00- +
-
50mg￥16025.0012820.00- +
-
100mg￥22437.0017950.00- +
- 货号: ajcx31648
- CAS: 886214-18-2
- 别名: GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium
- 分子式: C22H20ClN2NaO4S
- 分子量: 466.91
- 纯度: ＞98%
- 溶解度: DMSO: 100 mg/mL (214.17 mM)
- 储存: 4°C, stored under nitroge
- 库存: 现货
Background
Vercirnon is an orally bioavailable antagonist of chemokine receptor 9 (CCR9) with an IC50 value of 5.4 nM for inhibition of CCL25-induced calcium mobilization in Molt-4 cells.1 It is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s = >10 ?M for all). It also inhibits CCL25-induced Molt-4 chemotaxis in 0.1% BSA/HBSS and in 100% human AB serum (IC50s = 3.5 and 33.4 nM, respectively), as well as chemotaxis of human T cells stimulated by retinoic acid (RA) and mouse and rat thymocytes. Vercirnon binds allosterically to the intracellular side of CCR9 and prevents G protein coupling.2
1.Walters, M.J., Wang, Y., Lai, N., et al.Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseJ. Pharmacol. Exp. Ther.335(1)61-69(2010) 2.Oswald, C., Rappas, M., Kean, J., et al.Intracellular allosteric antagonism of the CCR9 receptorNature540(7633)462-465(2016)
